Background Currently we have biological treatments for control juvenile idiopathic arthritis (JIA), we have specific protocols that help us to handle, and do not know the exact time they keep these treatment, which conducted this study survival the biological agent.
Objectives The purpose this work is describe the survival time of biological drugs used in patients diagnosed with JIA, excluding the form systemic, in a pediatric unit of a children's hospital in the last 5 years.
Methods Descriptive analytic study of patients diagnosed with JIA (non-systemic) (as proposed by ILAR nomenclature, Edmonton 2001), who received biological treatment from 1 January 2010 to 30 June 2015. It considered as an event end the suspension of treatment by state remission or change to regimen decrease. Statistical analysis performed using the Kaplan-Meier and log rank test with SPSS.19.0 program.
Results Total 90 patients diagnosed with JIA with biological treatment in the last 5 years, 2/3 female (60 girls, 66.7%), 1/3 male (30 boys, 33.3%), mean age 5 years 2 months (minimum: 1 year 11 months, maximum: 15 years 6 months). The distribution of JIA: Oligoarticular arthritis 40% (42 patients). Polyarticular RF negative arthritis 22.9% (24 patients). Enthesitis-Related arthritis 15.2% (16 patients). Polyarticular RF positive arthritis 3.8% (4 patients). Psoriatic arthritis 3.8% (4 patients).
Total 100 treatments: 49% adalimumab, 46% etanercept, 5% Tocilizumab. Median time of 36 months overall monitoring (SD ± 21.8). Continue with the drug 45 patients, 45 achieved remission or regimen decrease (23 adalimumab, 20 etanercept, 2 tocilizumab), replaced by inefficiency 7, suspended for toxicity 3. Namely 45 and 55 censored events cases.
Medians for survival time: 56 months adalimumab (95% CI 46.5–65.5), 48 months etanercept (95% CI 38.8–57.2), Tocilizumab 46 months.
The comparison between the survival curves of etanercept and adalimumab (Logrank) was 0.092 (p=0.762).
Conclusions The time when “survive” (remain) biological treatment are significantly prolonged, over 4 years, with little difference between the two treatments used (etanercept and adalimumab). In addition, it can be deduced that serious side effects are rare, since in this cohort were replaced only in three cases by significant adverse effects.
No significant differences in the comparison of the survival curves of the main biological treatments used were found.
Disclosure of Interest None declared